title: [The effect of treatment on interleukin-1beta production in patients with first episode of juvenile psychosis].
abstract: Fifty-six patients (mean age 21,5+/-0,4 years) with first episode of endogenous psychosis (ICD-10 diagnosis F20.0, F20.2, F25) were studied before and after 4 and 8 weeks of the treatment with haloperidol and clozapine. The level of interleukin-1beta (IL-1beta) production increased significantly (p<0,05) in responders in the total group compared to the control one before and after the treatment. In patients with the prevalence of catatonic and catatonic-hallucinatory-delusion disorders, the increase of IL-1beta production was significant only to the 4-8 week of treatment. The increased level of cytokine production in patients with the prevalence of delusion and hallucinatory-delusion disorders reached a significance level (p<0,01) only in responders at all stages of the study. In non-responders, this index was similar to normal but significantly differed as compared to the subgroup of responders (p<0,05). In patients with affective and delusion disorders, the level of IL-1beta production did not differ from the controls during the treatment. In conclusion, the therapy proved more effective in patients with higher levels of IL-1beta production that suggests this index as a marker of immune system activation and a predictor of therapeutic efficacy.
authors: L V
authors: LV
authors: Androsova
authors: V G
authors: VG
authors: Kaleda
authors: A N
authors: AN
authors: Barkhatova
authors: M Ia
authors: MIa
authors: Tsutsul'kovskaia
authors: G I
authors: GI
authors: Koliaskina
mesh_terms: D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D003024:Clozapine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005500:Follow-Up Studies; D006220:Haloperidol / Q000627:therapeutic use*; D006801:Humans; D053583:Interleukin-1beta / Q000096:biosynthesis* / Q000187:drug effects; D008297:Male; D011618:Psychotic Disorders / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D012189:Retrospective Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D015415:Biomarkers; D053583:Interleukin-1beta; D003024:Clozapine; D006220:Haloperidol